Biomarin Pharmaceutical Inc. - Registered Shares

NASDAQ:BMRN   3:59:55 PM EDT
82.51
+0.44 (+0.54%)
Products, Regulatory

Biomarin - European Medicines Agency Granted Its Request For Accelerated Assessment Of Valoctocogene Roxaparvovec, For Adults With Severe Hemophilia A

Published: 05/24/2021 13:07 GMT
Biomarin Pharmaceutical Inc. - Registered Shares (BMRN) - Biomarin - European Medicines Agency Granted Its Request for Accelerated Assessment of Valoctocogene Roxaparvovec, for Adults With Severe Hemophilia A.
Biomarin Pharmaceutical - Ema Committee for Medicinal Products for Human Use Opinion is Expected in First Half of 2022.
Biomarin - Plans to Submit Marketing Authorization Application for Valoctocogene Roxaparvovec for Treatment of Severe Hemophilia a in June 2021.